Form 20-F 2005
Form 20-F 2005
Form 20-F 2005
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
The table below sets forth an analysis of our operating profit and loss for the years ended December 31, <strong>20</strong>04 and <strong>20</strong>05:<br />
(in millions of euros) <strong>20</strong>05 <strong>20</strong>04<br />
Net sales 5,085 4,693<br />
Other revenue 460 453<br />
Cost of sales (4,6<strong>20</strong>) (4,408)<br />
Administrative and selling expenses (574) (513)<br />
Research and development expenditure (124) (138)<br />
Restructuring costs (87) (169)<br />
Goodwill impairment (60)<br />
Other operating income/(expenses) (43) (46)<br />
Operating profit/(loss) 97 (188)<br />
Net sales<br />
Our net sales totaled €5,085 million in <strong>20</strong>05, up 8.4% compared with <strong>20</strong>04, primarily due to the increase in the net sales of Coatis,<br />
Polyamide and, to a lesser extent, Silcea. The impact of currency fluctuations on net sales amounted to €135 million. These<br />
fluctuations were essentially due to the appreciation of the Brazilian real against the euro. The negative impact of changes in the<br />
scope of continuing operations amounted to €14 million.<br />
The growth in our net sales in <strong>20</strong>05 was driven essentially by price increases totaling €347 million and representing a 7.4% increase<br />
in net sales, excluding the negative impact of transactional currency fluctuations of €100 million. Demand levels remained generally<br />
favorable throughout <strong>20</strong>05, except in the phosphorous derivatives and adipic acid markets.<br />
The table below sets forth our estimates of the effects of changes in the scope of consolidation, exchange rates, price and volume<br />
on our consolidated net sales by enterprise for the years ended December 31, <strong>20</strong>04 and <strong>20</strong>05. See “Presentation of Financial and<br />
Other Information”.<br />
(in millions of euros, unaudited)<br />
<strong>20</strong>05<br />
net sales Structure (2) Exchange<br />
rate Volume<br />
Selling<br />
price<br />
<strong>20</strong>04<br />
net sales<br />
Novecare 935 (42) 2 (15) 62 928<br />
Silcea 810 (15) 8 37 32 748<br />
Coatis 582 26 28 13 33 482<br />
Polyamide 1,749 16 95 (9) 89 1,558<br />
Acetow 410 4 8 7 (4) 395<br />
Eco services <strong>20</strong>9 2 6 <strong>20</strong>1<br />
Organics 349 3 1 (13) 21 337<br />
RPS 172 (1) 1 (10) 6 176<br />
Other (1) (131) (5) (8) 12 2 (132)<br />
Total 5,085 (14) 135 24 247 4,693<br />
(1) Includes the sales of other activities, sales on behalf of non-Group companies and the elimination of inter-company sales.<br />
(2) Presents the impact of changes in scope of continuing operations not classified as discontinued operations and the reclassifications of inter-company activities.<br />
42 <strong>Form</strong> <strong>20</strong> - F <strong>20</strong>05 - Rhodia